WuXi Biologics (Cayman) Inc.

SEHK:2269 Stock Report

Market Cap: HK$94.0b

WuXi Biologics (Cayman) Future Growth

Future criteria checks 3/6

WuXi Biologics (Cayman) is forecast to grow earnings and revenue by 14.4% and 12.1% per annum respectively. EPS is expected to grow by 13.8% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

14.4%

Earnings growth rate

13.78%

EPS growth rate

Life Sciences earnings growth31.7%
Revenue growth rate12.1%
Future return on equity10.16%
Analyst coverage

Good

Last updated07 May 2025

Recent future growth updates

Recent updates

WuXi Biologics (Cayman) Inc.'s (HKG:2269) 27% Jump Shows Its Popularity With Investors

May 08
WuXi Biologics (Cayman) Inc.'s (HKG:2269) 27% Jump Shows Its Popularity With Investors

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

May 07
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Mar 16
WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
author-image

Follow The Molecule Strategy And Global Expansion Will Secure Future Opportunities

Feb 09 Robust pipeline growth with new projects and North American focus drive future revenue and stabilize amidst geopolitical tensions.

WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark

Jan 25
WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Dec 17
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Earnings and Revenue Growth Forecasts

SEHK:2269 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202728,0475,6093,8198,42321
12/31/202624,3334,7322,4277,13326
12/31/202521,2134,0001,7836,46625
12/31/202418,6753,3561,2885,217N/A
9/30/202417,8962,9944834,219N/A
6/30/202417,1162,632-3223,220N/A
3/31/202417,0753,0161453,944N/A
12/31/202317,0343,4006124,668N/A
9/30/202316,7943,776N/AN/AN/A
6/30/202316,5544,1521,2696,834N/A
3/31/202315,9114,2864716,188N/A
12/31/202215,2694,420-3275,542N/A
9/30/202214,1794,251N/AN/AN/A
6/30/202213,0904,081-1,0284,091N/A
3/31/202211,6903,735-2,0523,761N/A
12/31/202110,2903,388-3,0773,431N/A
9/30/20219,1833,092-4,0062,840N/A
6/30/20218,0752,795-4,9362,249N/A
3/31/20216,8442,242-4,5402,065N/A
12/31/20205,6121,689-4,1441,881N/A
9/30/20204,9671,494-4,0491,649N/A
6/30/20204,3211,300-3,9541,417N/A
3/31/20204,1521,157-2,9791,312N/A
12/31/20193,9841,014-2,0041,208N/A
9/30/20193,535922-1,3561,035N/A
6/30/20193,087831-708861N/A
3/31/20192,811731-810811N/A
12/31/20182,534631-912762N/A
9/30/20182,277520N/A508N/A
6/30/20182,019410N/A255N/A
3/31/20181,819331N/A308N/A
12/31/20171,619253N/A360N/A
9/30/20171,429177N/A320N/A
6/30/20171,233149N/A369N/A
3/31/20171,111145N/A226N/A
12/31/2016989141N/A82N/A
9/30/2016889171N/A162N/A
12/31/201555745N/A107N/A
12/31/201433242N/A22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2269's forecast earnings growth (14.4% per year) is above the savings rate (2.4%).

Earnings vs Market: 2269's earnings (14.4% per year) are forecast to grow faster than the Hong Kong market (10.4% per year).

High Growth Earnings: 2269's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2269's revenue (12.1% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 2269's revenue (12.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (10.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 23:49
End of Day Share Price 2025/05/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Jian Xiong LimCFRA Equity Research